samedan logo
 
 
spacer
home > ebr > spring 2007 > systems and networks
PUBLICATIONS
European BioPharmaceutical Review

Systems and Networks

Kate Rowley at Nexxus traces the life science networks that enhance knowledge transfer and finds that the end product is greater than the sum of its parts

Given the growing interest in the area of drug development through the use of systems biology – both at a molecular level and within a whole organism – it is clear that the value of interactions can no longer be defined in terms of a single exchange of a signal from source to recipient. In a similar way, regional and national networks are not focused on single exchanges of information within the region, but look to amplify these signals through transfer and dialogue across their numerous interfaces. This article explores the ways in which networks – whether their purpose is the exchange of cellular signals or of knowledge – act to amplify the messages they create.

UNDERSTANDING NETWORKS

The emerging field of systems biology includes a strong focus on the network perspective within biological systems. This is of particular significance within the realm of drug discovery, which used to be built on, at most, tissue-level screens but, more often, relied on simple cell-based pathway screens. The identification of targets involved blocking the interactions of individual molecules at a single junction of the cell processes, often in isolation from the background melee of cellular signals they were operating within.

In the advent of understanding the role that whole systems play, it seems that methodologies that filter information for significance, such as biological context and relevance, are now being regarded as crucial to the successful understanding of different levels of organisation in systems biology research. Today, biologists are looking at the organisation of interacting proteins and protein complexes into networks, and these networks are being examined to elucidate underlying principles and activities that will enable us to understand how to influence a disease process. In fact, more and more information is being sought on how functional relationships exist within biological networks and how signals may be amplified within them. Understanding how such networks operate is key to being able to manipulate changes within the biological systems. So, progress is being made in understanding the effectiveness of networks in their ability to control messages through mechanisms such as signal amplification and noise filtering.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

spacer
Dr Kate Rowley joined Nexxus, The West of Scotland Bioscience Network, in January 2006. Her background is in molecular biology, specialising in Virology having gained a PhD from the University of Reading studying influenza. She has worked for Wellcome and the NHS, as well as the Medical Research Council. Prior to Nexxus, Kate was Head of Knowledge Transfer at the Scottish Association for Marine Science at Dunstaffnage, Oban. In this post she experienced a wide range of technological disciplines – from geochemistry to biotechnology and numerous facets in between. She was also the Business Development Manager for the European Centre for Marine Biotechnology.
spacer
Dr Kate Rowley
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

New PFA SonicLine® ultrasonic flowmeters

Flow measurement with ultrasound fast, precise, free from contamination         The new PFA SonicLine® ultrasonic flowmeters assure precise measurement and control of chemical consumption and management of chemical stocks with high reliability. SonicLine® is also ideally suited for accurate batch and dosing processes with high reproducibility.              
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement